Paul Tudor Jones’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.52M Buy
+39,644
New +$7.46M 0.01% 1010
2025
Q4
Sell
-19,643
Closed -$3.45M 3492
2025
Q3
$3.01M Sell
19,643
-15,945
-45% -$2.41M 0.01% 1531
2025
Q2
$4.97M Buy
35,588
+17,950
+102% +$2.52M 0.01% 1091
2025
Q1
$2.59M Buy
17,638
+1,588
+10% +$230K 0.01% 1163
2024
Q4
$2.1M Buy
+16,050
New +$2.25M 0.01% 1226
2023
Q4
Sell
-3,237
Closed -$421K 2364
2023
Q3
$438K Buy
+3,237
New +$442K ﹤0.01% 1738
2023
Q1
Sell
-11,772
Closed -$1.6M 2398
2022
Q4
$1.6M Sell
11,772
-34,605
-75% -$4.34M 0.03% 774
2022
Q3
$5.09M Buy
+46,377
New +$5.88M 0.11% 220
2014
Q3
Sell
-27,100
Closed -$2.01M 1344
2014
Q2
$2.01M Buy
+27,100
New +$1.96M 0.08% 108

Other funds holding AZN

Paul Tudor Jones's AZN Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in AstraZeneca (AZN) in Q2 2026: 39,644 shares worth $7.52M. The stake represents 0.01% of the portfolio and ranks #1010 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in AZN as recently as Q3 2025.

Paul Tudor Jones first reported a position in AZN in Q2 2014 and has held it in 9 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Paul Tudor Jones held 39,644 shares of AstraZeneca worth $7.52M as of Q2 2026.
  • AstraZeneca was a new Paul Tudor Jones position in Q2 2026.
  • AstraZeneca made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1010 holding.
  • Paul Tudor Jones first reported a position in AstraZeneca in Q2 2014 and has held it in 9 quarters since.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.